Japanese pharmaceutical company Otsuka Pharmaceutical has made one of Big Pharma’s first pivots into the psychedelics space with the acquisition of Mindset Pharma.
Global investment firm Psych Capital has agreed to acquire 100% of the issued share capital of Shortwave Pharma Inc.,
PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and opportunities in the field of psychedelic...
Dr Devon Christie, Medical and Therapeutic Services Director with Numinus, speaks to Psychedelic Health about the representation of women in the field of psychedelics – from...
Irwin Naturals has signed a Letter of Intent entering into a partnership with Braxia Scientific – which is developing innovative ketamine and psilocybin treatments for mental...
Algernon Pharmaceuticals (AGN Pharma) has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its DMT stroke programme.
The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.
Psychedelics venture studio Nucleus has raised USD$135,000 from investors through its Wefunder campaign.
Former Red Bull Canada and Juul Labs Canada executive, Nicholas Kadysh, has been appointed to the role of Executive Special Advisor by Clearmind Medicine.